Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension
Recent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/20458940211010371 |
| _version_ | 1818117585674174464 |
|---|---|
| author | Ghaleb Khirfan Manshi Li Xiaofeng Wang Joseph A. DiDonato Raed A. Dweik Gustavo A. Heresi |
| author_facet | Ghaleb Khirfan Manshi Li Xiaofeng Wang Joseph A. DiDonato Raed A. Dweik Gustavo A. Heresi |
| author_sort | Ghaleb Khirfan |
| collection | DOAJ |
| description | Recent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 and its oxidative state might be more sensitive biomarkers in CTEPH. Plasma levels of HDL-C, ApoA-I, paraoxonase-1 enzyme activity (PON1), and the oxidized dysfunctional ApoA-I (oxTrp72-ApoA-I) were measured in patients with CTEPH and compared to those in healthy controls. Association with markers of disease severity in CTEPH was assessed. We included a total of 61 patients with CTEPH (age: 61.2 ± 15 years; male 52.5%) and 28 control subjects (age: 60.1 ± 8 years; male 59.3%). When adjusting for age, sex, body mass index, and statin use, ApoA-I was lower in CTEPH compared to controls (CTEPH:125.2 ± 27 mg/dl; control:158.3 ± 29.4 mg/dl; p < 0.001), but HDL-C levels were not statistically different. There were no significant differences in PON and oxTrp72-ApoA-I/ApoA-I ratio. In exploratory analyses, ApoA-I was associated with mean right atrial pressure (r s = −0.32, p = 0.013) and N-terminal pro B-type natriuretic peptide (r s = −0.31, p = 0.038). There were no significant associations between HDL-C, PON1, or oxTrp72-ApoA-I/ApoA-I ratio and markers of disease severity. We conclude that ApoA-I is a more sensitive biomarker than HDL-C in CTEPH, and may be associated with right heart dysfunction. |
| first_indexed | 2024-12-11T04:40:45Z |
| format | Article |
| id | doaj.art-14937cb13d004de29013b6993c0393d6 |
| institution | Directory Open Access Journal |
| issn | 2045-8940 |
| language | English |
| last_indexed | 2024-12-11T04:40:45Z |
| publishDate | 2021-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj.art-14937cb13d004de29013b6993c0393d62022-12-22T01:20:37ZengWileyPulmonary Circulation2045-89402021-04-011110.1177/20458940211010371Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertensionGhaleb KhirfanManshi LiXiaofeng WangJoseph A. DiDonatoRaed A. DweikGustavo A. HeresiRecent studies have shown low high-density lipoprotein cholesterol (HDL-C) and dysregulated lipid metabolism in chronic thromboembolic pulmonary hypertension (CTEPH). Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-C and mediates most of its functions. We hypothesize that ApoA-1 and its oxidative state might be more sensitive biomarkers in CTEPH. Plasma levels of HDL-C, ApoA-I, paraoxonase-1 enzyme activity (PON1), and the oxidized dysfunctional ApoA-I (oxTrp72-ApoA-I) were measured in patients with CTEPH and compared to those in healthy controls. Association with markers of disease severity in CTEPH was assessed. We included a total of 61 patients with CTEPH (age: 61.2 ± 15 years; male 52.5%) and 28 control subjects (age: 60.1 ± 8 years; male 59.3%). When adjusting for age, sex, body mass index, and statin use, ApoA-I was lower in CTEPH compared to controls (CTEPH:125.2 ± 27 mg/dl; control:158.3 ± 29.4 mg/dl; p < 0.001), but HDL-C levels were not statistically different. There were no significant differences in PON and oxTrp72-ApoA-I/ApoA-I ratio. In exploratory analyses, ApoA-I was associated with mean right atrial pressure (r s = −0.32, p = 0.013) and N-terminal pro B-type natriuretic peptide (r s = −0.31, p = 0.038). There were no significant associations between HDL-C, PON1, or oxTrp72-ApoA-I/ApoA-I ratio and markers of disease severity. We conclude that ApoA-I is a more sensitive biomarker than HDL-C in CTEPH, and may be associated with right heart dysfunction.https://doi.org/10.1177/20458940211010371 |
| spellingShingle | Ghaleb Khirfan Manshi Li Xiaofeng Wang Joseph A. DiDonato Raed A. Dweik Gustavo A. Heresi Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension Pulmonary Circulation |
| title | Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension |
| title_full | Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension |
| title_fullStr | Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension |
| title_full_unstemmed | Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension |
| title_short | Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension |
| title_sort | abnormal levels of apolipoprotein a i in chronic thromboembolic pulmonary hypertension |
| url | https://doi.org/10.1177/20458940211010371 |
| work_keys_str_mv | AT ghalebkhirfan abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension AT manshili abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension AT xiaofengwang abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension AT josephadidonato abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension AT raedadweik abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension AT gustavoaheresi abnormallevelsofapolipoproteinaiinchronicthromboembolicpulmonaryhypertension |